AZN Q3 2026 Earnings Results — AstraZeneca PLC
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is AZN's next earnings date?
AstraZeneca PLC (AZN) has not announced its next earnings date yet. Its most recent earnings report was on Friday, October 30, 2026.
How did AZN do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), AstraZeneca PLC posted EPS of $2.79 versus the $2.60 estimate, a beat of 7.3%. Revenue was $16.21B against a $16.00B estimate.
How much does AZN stock move after earnings?
AZN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 2.1% (up or down) in the day after earnings.
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
🤖 AI Earnings Analysis
AstraZeneca’s cancer-drug sales drove profit growth, supporting a strong quarter for the global drugmaker: net profit rose to $3.12B from $2.54B year over year, while EPS beat estimates by $0.19 at $2.79.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | 2.60 | 2.79 | +7.31% | $16.21B | ✅ Beat | — | — | — |
| 2026-07-27 | Q2 2026 | 1.52 | 2.63 | +73.03% | $15.38B | ✅ Beat | +0.22% | +0.22% | -0.86% |
| 2026-04-29 | Q1 2026 | 1.53 | 2.58 | +68.63% | $15.29B | ✅ Beat | -0.79% | -2.91% | -0.72% |
| 2026-02-10 | Q4 2025 | 2.18 | 2.12 | -2.75% | $15.50B | ❌ Miss | +2.87% | +11.42% | +3.90% |
| 2025-11-06 | Q3 2025 | 1.14 | 1.19 | +4.39% | $15.19B | ✅ Beat | +3.22% | +8.05% | +11.12% |
| 2025-07-29 | Q2 2025 | 1.10 | 1.08 | -1.36% | $14.46B | ❌ Miss | +2.99% | +3.84% | +12.20% |
| 2025-04-29 | Q1 2025 | 1.11 | 1.25 | — | $13.59B | ✅ Beat | +2.55% | +3.09% | +0.64% |
| 2025-02-06 | Q4 2024 | 1.07 | 1.04 | -2.34% | $14.89B | ❌ Miss | +2.01% | +4.92% | +10.77% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY23 · $16.98B total
| Segment | Share | Revenue | YoY | Q2 FY21 | Q2 FY22 | Q2 FY23 |
|---|---|---|---|---|---|---|
| Total Oncology | 25.8% | $4.38B | +173.0% | — | $1.60B | $4.38B |
| Farxiga | 8.9% | $1.50B | +447.3% | $732.0M | $275.0M | $1.50B |
| Tagrisso | 8.8% | $1.49B | +190.6% | $1.31B | $513.0M | $1.49B |
| BioPharmaceuticals: total Respiratory & Immunology | 8.7% | $1.48B | +126.8% | — | $654.0M | $1.48B |
| Imfinzi | 6.3% | $1.08B | +187.7% | $604.0M | $374.0M | $1.08B |
| Soliris | 4.8% | $814.0M | +41.8% | — | $574.0M | $814.0M |
| Lynparza | 4.2% | $717.0M | +129.8% | $588.0M | $312.0M | $717.0M |
By region
FY2025 · $58.74B total · annual
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| The Americas | 46.9% | $27.56B | — |
| Europe excluding the United Kingdom | 22.9% | $13.46B | — |
| Asia, Africa And Australasia | 22.8% | $13.37B | — |
| UNITED KINGDOM | 7.4% | $4.36B | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.